The estimated Net Worth of Gregory John Carven is at least $4.05 Million dollars as of 26 January 2021. Dr Carven owns over 55,874 units of Scholar Rock Corp stock worth over $233,413 and over the last 4 years he sold SRRK stock worth over $3,265,277. In addition, he makes $551,333 as Chief Scientific Officer at Scholar Rock Corp.
Dr has made over 1 trades of the Scholar Rock Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 55,874 units of SRRK stock worth $3,265,277 on 26 January 2021.
The largest trade he's ever made was selling 55,874 units of Scholar Rock Corp stock on 26 January 2021 worth over $3,265,277. On average, Dr trades about 11,175 units every 0 days since 2021. As of 26 January 2021 he still owns at least 26,860 units of Scholar Rock Corp stock.
You can see the complete history of Dr Carven stock trades at the bottom of the page.
Dr. Gregory John Carven Ph.D. is the Chief Scientific Officer at Scholar Rock Corp.
As the Chief Scientific Officer of Scholar Rock Corp, the total compensation of Dr D at Scholar Rock Corp is $551,333. There are 4 executives at Scholar Rock Corp getting paid more, with Dr. Nagesh K. Mahanthappa MBA, Ph.D. having the highest compensation of $1,372,681.
Dr D is 45, he's been the Chief Scientific Officer of Scholar Rock Corp since . There are 9 older and 2 younger executives at Scholar Rock Corp. The oldest executive at Scholar Rock Holding Corp is Michael Gilman, 65, who is the Independent Director.
Over the last 6 years, insiders at Scholar Rock Corp have traded over $8,613,447 worth of Scholar Rock Corp stock and bought 8,895,194 units worth $64,726,758 . The most active insiders traders include Timothy A Springer, Srinivas Akkaraju, and Amir Nashat. On average, Scholar Rock Corp executives and independent directors trade stock every 55 days with the average trade being worth of $1,953,616. The most recent stock trade was executed by Caryn Parlavecchio on 16 August 2024, trading 1,451 units of SRRK stock currently worth $13,538.
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s
Scholar Rock Corp executives and other stock owners filed with the SEC include: